Molecular Profiling of Lung Cancer

Message from the Guest Editor

Dear Colleagues,

High-throughput technologies have enabled the molecular profiling of lung cancer, allowing for refined risk assessments, as well as the development of non-invasive screening methods or therapeutic interventions for lung cancer. The objective of this Special Issue is to publish the latest findings in the molecular profiling/signatures of lung cancer aimed toward clinical implementation.

Topics of this Special Issue include, but are not limited to:

- Molecular profiling/signatures that can classify lung cancers into specific subtypes with different clinical outcomes or sensitivities to specific treatments.
- Molecular profiling/signatures that allow the determination of useful biomarkers for liquid biopsy.
- Molecular profiling/signatures that allow the determination of biomarkers for acquired resistance to specific drugs.

Target topics (examples are described above) are comprehensive and will give a thorough view of the increasing knowledge of molecular profiling/signatures of lung cancer.

Dr. Kentaro Inamura
Guest Editor

Deadline for manuscript submissions: closed (30 June 2019)
Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High visibility: indexed by the Science Citation Index Expanded (Web of Science) and BIOSIS Previews, Scopus and other databases. Citations available in PubMed, full-text archived in PubMed Central.
Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 15.0 days after submission; acceptance to publication is undertaken in 4.0 days (median values for papers published in this journal in the second half of 2019).

Contact Us

Cancers
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland
Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com
mdpi.com/journal/cancers
cancers@mdpi.com
@Cancers_MDPI